Literature DB >> 22981

Kinetics of the binding of salicylazosulfapyridine to human serum albumin.

J A Jansen.   

Abstract

In order to elucidate the possibility of the dissociation rate of drugs from plasma proteins presenting a rate limiting step in the elimination of drugs by secretion (renal or biliary) and metabolism, the kinetics of salicylazosulfapyridine (SASP) binding to human serum albumin (HSA) has been investigated by stopped-flow photometry. Equilibrium dialysis showed that HSA has three classes of binding sites for SASP with 0.93, 2.3 and 8.4 sites, respectively, and association constants of 2.1.10(6), 1.4.10(5) and 3.0.10(3) M-1, respectively. The association rate constants for the first and second classes are 4.4.10(6) and 1.5.10(7) M-1 sec.-1, and the dissociation rate constants are 2.1 and 109 sec.-1. At SASP concentrations resulting from the usual therapeutic doses about 83% will bind to the first class binding sites. The dissociation "half time" for this class being 0.34 sec., leads to the conclusion that dissociation rates of this order of magnitude are unlikely to reduce the rate of metabolism or biliary secretion whereas it may reduce renal tubular secretion. Whether this is the case depends on the intrinsic rate constant of secretion.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 22981     DOI: 10.1111/j.1600-0773.1977.tb02151.x

Source DB:  PubMed          Journal:  Acta Pharmacol Toxicol (Copenh)        ISSN: 0001-6683


  7 in total

1.  Age-dependence and free fatty acid modulation of binding kinetics at the benzodiazepine binding site of serum albumin in neonates and adults determined using fast reaction methods.

Authors:  G Menke; P Pfister; S Sauerwein; I Rietbrock; B G Woodcock; N Rietbrock
Journal:  Br J Clin Pharmacol       Date:  1987-04       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Influence of plasma protein binding kinetics on hepatic clearance assessed from a "tube" model and a "well-stirred" model.

Authors:  J A Jansen
Journal:  J Pharmacokinet Biopharm       Date:  1981-02

Review 4.  Clinical pharmacokinetics of sulphasalazine, its metabolites and other prodrugs of 5-aminosalicylic acid.

Authors:  U Klotz
Journal:  Clin Pharmacokinet       Date:  1985 Jul-Aug       Impact factor: 6.447

5.  Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs.

Authors:  J van der Heijden; M C de Jong; B A C Dijkmans; W F Lems; R Oerlemans; I Kathmann; G L Scheffer; R J Scheper; Y G Assaraf; G Jansen
Journal:  Ann Rheum Dis       Date:  2004-02       Impact factor: 19.103

6.  Serum protein binding of propylthiouracil.

Authors:  J P Kampmann; J E Mølholm Hansen
Journal:  Br J Clin Pharmacol       Date:  1983-11       Impact factor: 4.335

7.  Effect of sulphasalazine on pulmonary inactivation of prostaglandin F2 alpha in the pig.

Authors:  P G Hellewell; J D Pearson
Journal:  Br J Pharmacol       Date:  1982-06       Impact factor: 8.739

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.